Integration of data from different omic platforms with clinical data could identify a biomarker panel
to improve stratification of MDS patients.
Abbreviations: BM, bone marrow; HLA, human leukocyte antigen; QOL/PRO,
quality of life/patient reported outcome.
Adopted from Winter, et al, JCO 2020
References
1. Komrokji RS, Kulasekararaj A, Al Ali NH, et al. Autoimmune diseases and myelodysplastic syndromes. Am
J Hematol. 2016;91(5):E280-283.
2. Kordasti SY, Ingram W, Hayden J, et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic
syndrome (MDS). Blood. 2007;110(3):847-850.
3. Griffiths EA, Srivastava P, Matsuzaki J, et al. NY-ESO-1 Vaccination in Combination with Decitabine
Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clin Cancer Res.
2018;24(5):1019-1029.
4. Sarhan D, Brandt L, Felices M, et al. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived
suppressor cells in MDS. Blood Adv. 2018;2(12):1459-1469.
5. Sallman DA, Donnellan WB, Asch AS, et al. The first-in-class anti-CD47 antibody Hu5F9-G4 is active and
well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results. Journal of Clinical
Oncology. 2019;37(15).
6. Spitzer MH, Carmi Y, Reticker-Flynn NE, et al. Systemic Immunity Is Required for Effective Cancer
Immunotherapy. Cell. 2017;168(3):487-+.
7. McGrail DJ, Federico L, Li YS, et al. Multi-omics analysis reveals neoantigen-independent immune cell
infiltration in copy-number driven cancers. Nature Communications. 2018;9.
8. Winter S, Shoaie S, Kordasti S, Platzbecker U. Integrating the "Immunome" in the Stratification of
Myelodysplastic Syndromes and Future Clinical Trial Design. J Clin Oncol. 2020 May 20;38(15):1723-1735. doi:
10.1200/JCO.19.01823. Epub 2020 Feb 14. PMID: 32058844.
9. Platzbecker U, Kordasti S. Natural born survivors: the inglorious TP53. Blood. 2020 Dec 10;136(24):2727-
2728. doi: 10.1182/blood.2020008212. PMID: 33301036.